👉 We spoke with @ShrutiPatelMD, an early-career gastrointestinal medical oncologist, on aspects of her clinical work with patients with GI cancers, where she reflects on the emotional and professional challenges that can accompany long-term patient care:

💊 New data has shown that trastuzumab deruxtecan as a second-line therapy may better improve survival rates in patients with HER2-positive gastric or gastroesophageal junction cancer over #ramucirumab with #paclitaxel:

🔎 As the predictive role of HER2 expression in determining treatment benefit from #bevacizumab is unclear, an analysis reviewed randomized trials to determine the impact of HER2 in patients with #colorectal cancer treated with chemotherapy & bevacizumab:

💊 A phase 2 study examined radiation therapy with #durvalumab and #tremelimumab for biliary tract cancer, finding the combination tolerable. 👉 Learn more about the results that were presented at #ASTRO25:

📺 We spoke with @dr_samehhany81 on his study that investigated the role of neoadjuvant #chemotherapy prior to simultaneous resection of #colorectal liver metastases. 👉 Learn more about the study’s results, including the improved 5-year OS rate: https://t.co/9V4fZiVSOX

📈 As the survivorship rates of #gastrointestinal cancers increases, the management of long-term toxicities will become more common. 🔎 We recently spoke with clinicians about the current and potential future safety landscape for survivors of GI cancers:

🔎 A recent study evaluated treatment with the triplet therapy of #cisplatin, #fluorouracil, and #docetaxel for patients with metastatic #EsophagealCarcinoma. 📰 Read more about the findings of the study here: https://t.co/PF8G7pe6kw

❗️ By 2030, #pancreatic ductal adenocarcinoma is projected to be the 2nd leading cause of cancer-related death in the US. 👉 A recent analysis evaluated the impact of KRAS variants to determine their impact on clinical outcomes and response to therapy:

👉 “To serve our patients best, every patient should be getting comprehensive molecular profiling." 📰 Hear from experts including @rachnatshroff on the advancing field of precision medicine in #biliary tract cancer, including approvals and challenges: https://t.co/Cjr55FFxlE

💊 The use of #zanidatamab for biliary tract cancer led to increased OS and duration of response in the HERIZON-BTC-01 trial. Review our coverage of the trial with @DrShubhamPant of @MDAndersonNews and Dr. Richard Kim of @MoffittNews:

📺 Dr. Stephanie Schmit of @ClevelandClinic discusses her study on the use of immunotherapy for patients with metastatic #colorectal cancer in real-world settings, including specific disease subtypes: https://t.co/rFh5uMmHKo

Listen in on this @GiOncNow #ASCO25 roundtable on #upperGI cancer breakthroughs with renowned #KOLs @NataliyaUboha Dr. Philip @vincentlamMD Dr. Gibson Dr. Dayyani 🙌 honored to have been invited to this discussion https://t.co/xqlqK4GseJ @OncoAlert

💊 In a study that examined the efficacy of #pazopanib for patients with extrapancreatic #neuroendocrine tumors, the treatment was found to significantly improved PFS rates - however, the occurrence of TRAEs weighed against the benefits of treatment:

📺 Dr. Suzanne George of @DanaFarber talks about the future of care for patients with #GISTs, including how multidisciplinary care can improve outcomes, what knowledge gaps still remain, and her outlook on the progression of care in the next few years: https://t.co/EslpuVgbjs

❗️Learn from the experts in your GI field of interest - we've met with a number of experts who have shared their knowledge for a variety of disease states. 👉Select which topic interests you the most, and we'll match you with an exclusive interview: https://t.co/t0hDLPtXzf

📺 Suzanne George, MD, of @DanaFarber, provides an in-depth overview of her review on the current challenges of treating patients with GISTs, including how to determine who benefits from adjuvant #imatinib, the development of resistance to TKIs, and more: https://t.co/5XB0xXRmJ8

⭐ In a new interview, we spoke with @CathyEngMD of @VUMChealth on the detailed safety analysis from FRESCO-2. 📺 She provides an overview of the study's outcomes, and emphasizes the importance of patient-provider communication in managing side effects: https://t.co/GRZj8tzIvQ

🔎 A recent study used pretreatment DPYD/UGT1A1 testing in patients with #gastrointestinal cancers to analyze the practice’s feasibility and efficacy: https://t.co/mI34WgJN2O 🧬 This genetic testing can help assess who may be at an increased risk of #chemotherapy side effects.

📋 A phase 3, randomized study aimed to determine whether adding #chemoradiotherapy to #chemotherapy boosts surgery eligibility for patients with #PancreaticCancer, with the hope of removing all visible cancer: https://t.co/UpOvYbnMwj

📺 Check out the Top 5 Expert Video Interviews from last month: https://t.co/qne8q9Zhxf ⭐ Gain insight from different experts across a wide range of topics including epigenetic editing for #CRC and #ctDNA as a curative tool for #LiverCancer management, to name a few.